News

Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), and Secretome Therapeutics, a biotechnology company advancing therapies derived…
Read More...

Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, announced it has been awarded a share of the £3…
Read More...

Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) approval of a supplemental New Drug Application (sNDA) for SPRAVATO (esketamine) CIII nasal spray, making…
Read More...

Shanghai Junshi Biosciences Co., Ltd, a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, and its…
Read More...

Dyne Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for DYNE-101 for the treatment of myotonic dystrophy type 1 (DM1).…
Read More...

Catalent, Inc., a leader in enabling the development and supply of better treatments for patients worldwide, announced a strategic collaboration with Galapagos NV (Euronext &…
Read More...

Axcynsis Therapeutics Pte Ltd ("Axcynsis"), a privately held biopharmaceutical company specialized in delivering Antibody Drug Conjugates (ADCs) with breakthrough potential, proudly…
Read More...

Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease…
Read More...

AbbVie and Simcere Zaiming, a subsidiary of Simcere Pharmaceutical Group Ltd announced an option to license agreement to develop SIM0500, an investigational new drug candidate. SIM0500…
Read More...

Be Biopharma, Inc. announced the closing of its $92M Series C financing. The round includes participation from new investor Nextech with existing investors including ARCH Venture…
Read More...

REGENXBIO Inc. and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) announced a strategic partnership for the development and commercialization of RGX-121 for the treatment of…
Read More...

Acadia Pharmaceuticals Inc. announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for trofinetide for the treatment…
Read More...

Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted Eisai’s Biologics License Application (BLA) for lecanemab-irmb (U.S. brand name:…
Read More...

Daiichi Sankyo Company, Ltd announced that it will pay Glycotope $132.5 million to acquire intellectual property rights of the anti-tumor-associated mucin-1 (TA-MUC1) antibody,…
Read More...

Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, announced the closing of a $100 million…
Read More...

Solid Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for SGT-212 for the treatment of…
Read More...

Dizal, a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the U.S. Food and Drug Administration…
Read More...

Amgen announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted a conditional marketing authorisation to IMDYLLTRA for the treatment of adult…
Read More...

Variant Bio, a genomics-driven drug discovery company, announced a multi-year research collaboration with Novo Nordisk to discover novel targets for the treatment of metabolic disease.…
Read More...

Tempest Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to amezalpat (TPST-1120), an oral, small molecule,…
Read More...